von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 7, 2007, Pages 1420-1430

  Lethagen, Stefan ^a,f   Kyrle, P A ^b   Castaman, G ^c,i   Haertel, S ^d   Mannucci, P M ^e,l   Auerswald, G ^g   Batlle, J ^h   Collins, P ^j   D'Amico, E ^k   Dasani, H ^j   Federici, A B ^l   Hassenpflug, W ^m   Heller, C ⁿ   Hernandez Navarro F ^o   Holmstrom M ^p   Ingerslev, Jørgen ^q   Keeling, D ^r   Klinge, J ^s   Krause, M ^t   Kreuz, W ^u   Lopez Fernandez F ^h   Ludlam, C A ^u   Miesbach, W ^t   Monteagudo, J ^v   Muntean, E W ^w   Negrier C ^x   Petrini, P ^p   Molina, M Quintana ^o   Ramschak, H ^y   Reverter, J C ^v   Scharrer, I ^t   Schneppenheim, R ^m   Schulman, S ^p   Schved, J F ^z   Scognamiglio, F ⁱ   Siebenhofer, A ^y   Spranger, T ^g   Tassies D ^v   Vallin, Sandra ^aa   Camacho, A Villar ^o   Prondzinski, M V Depka ^ab   Weltermann, V ^b   more..

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Hospital of Vicenza   (Italy)

^d CSL BEHRING GMBH   (Germany)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f Rigshospitalet   (Denmark)

^g Prof Hess Kinderklinik   (Germany)

^h HOSPITAL JUAN CANALEJO   (Spain)

ⁱ Ospedale Di Vicenza   (Italy)

^j UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l UNIVERSITY OF MILAN   (Italy)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q AARHUS UNIVERSITY HOSPITAL   (Denmark)

^r CHURCHILL HOSPITAL   (United Kingdom)

^s UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^t GOETHE UNIVERSITY   (Germany)

^u ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^v HOSPITAL CLÍNIC   (Spain)

^w Universitatsklinik fur Kinder und J   (Austria)

^x EDOUARD HERRIOT HOSPITAL   (France)

^y UNIVERSITY HOSPITAL GRAZ   (Austria)

^z HÔPITAL SAINT ELOI   (France)

^aa FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^ab HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Factor VIII; Hereditary diseases; Postoperative hemorrhage; Prospective studies; Surgical hemostasis; Von Willebrand factor

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; CYCLOOXYGENASE 2 INHIBITOR; FIBRIN GLUE; HEPARIN; RISTOCETIN; TRANEXAMIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; ELECTIVE SURGERY; FEASIBILITY STUDY; FEMALE; HEMOSTASIS; HUMAN; IN VIVO STUDY; LEG THROMBOPHLEBITIS; LOADING DRUG DOSE; LUNG EMBOLISM; MALE; MULTICENTER STUDY; OPEN STUDY; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; VOMITING; VON WILLEBRAND DISEASE;

EID: 34250691461     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02588.x     Document Type: Article

References (47)

1. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
2. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: A survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235-41.
3. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S17-21.
4. Chang AC, Rick ME, Ross Pierce L, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4 (Suppl. 3): 1-6.
5. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: The French experience. Haemophilia 1998; 4 (Suppl. 3): 48-52.
6. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001; 7 (Suppl. 1): 10-5.
7. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
8. Walter O, Budde U, Suiter TM. Determination of high-molecular weight von Willebrand factor multimers and their impact on specific VWF-activities in VWF/FVIII concentrates. J Thromb Haemost 2003; Suppl. 1: P1673.
9. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: Effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984;63: 128-39.
10. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: Affinity is related to multimeric size. Br J Haematol 1989; 73: 93-9.
11. Furlan M. Von Willebrand factor: Molecular size and functional activity. Ann Hematol 1996; 72: 341-8.
12. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Müller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 (Suppl. 3): 25-32.
13. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-9.
14. Schimpf K, Mannucci PM, Kreutz W, Brackmann HH, Auerswald G, Ciavarella N, Mosseler J, DeRosa V, Kraus B, Brueckmann C, Mancuso G, Mittler U, Haschke F, Morfini M. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 1987; 316: 918-22.
15. Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate P in children with von Willebrand's disease. Haemostasis 1994; 24: 304-10.
16. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (Suppl. 3): 33-9.
17. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
18. Muntean W, Zenz W, Falger J, Male C, Streif W, Wank J, Schwarz R, Schmitt K, Kurnik P, Zwiauer K. Sixteen years of treatment with pasteurized human clotting factor concentrates in children and adolescents: A pharmacosurveillance investigation comprising 727 patient years. Semin Thromb Hemost 2002; 28 (Suppl. 1): 63-74.
19. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
20. Alusi GH, Grant WE, Lee CA, Pasi KJ, Stearns MP. Bleeding after tonsillectomy in severe von Willebrand's disease. J Laryngol Otol 1995; 109: 437-9.
21. Naqvi A, Endres-Brooks J, Montgomery RR, Stain M, Sparling C, Klaassen R, Blanchette V. Successful cardiac surgery in a young girl with type 2a von Willebrand disease using continuous infusion of Haemate-P. Thromb Haemost 1997; 77 (Suppl.): 514.
22. Lethagen S. Haemostatic treatment in connection with surgery in patients with von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 64-7.
23. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229-33.
24. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 280-4.
25. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-83.
26. Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004; 15: 323-30.
27. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5.
28. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous 'venostasis'bleeding time technique. J Lab Clin Med 1941; 84: 160-74.
29. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
30. Casella G. Refining binomial confidence intervals. Can J Stat 1986; 14: 113-29.
31. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 4 (Suppl. 3): 15-24.
32. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): Use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
33. Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998; 4 (Suppl. 3): 44-7.
34. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
35. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
36. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
37. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
38. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
39. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, Prins MH, van der Meer J, Buller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
40. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
41. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-3.
42. Mont MA, Jones LC, Rajadhyaksha AD, Shuler MS, Hungerford DS, Sieve-Smith L, Wang P, Cordista AG, Glueck CJ. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res 2004; 154-63.
43. Tirado I, Mateo J, Soria JM, Oliver A, Martinez-Sanchez E, Vallve C, Borrell M, Urrutia T, Fontcuberta J. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-74.
44. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005; 93: 842-6.
45. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
46. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CR, Hill FG, Laffan M, Peake IR. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors'Organization. Haemophilia 2004; 10: 218-31.
47. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.